FDA extends review of Praxis drug for rare epilepsy to December 2026
Go back to FDA extends review of Praxis drug for rare epilepsy to December 2026| (NASDAQ: PRAX) | Delayed: 298.95 -11.52 (3.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $310.47 | 52 Week High | $ | |||
| Open | $312.76 | 52 Week Low | $ | |||
| Day High | $314.01 | P/E | N/A | |||
| Day Low | $295.71 | EPS | $ | |||
| Volume | 829,853 | |||||
